Befotertinib is under clinical development by InventisBio and currently in Phase II for Lung Adenocarcinoma. According to GlobalData, Phase II drugs for Lung Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Befotertinib LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Befotertinib overview

Befotertinib (Semena) is the third epidermal growth factor receptor tyrosine kinase inhibitor which acts as antineoplastic agent. It is formulated as capsules for oral route of administration. Semena is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer who have progressed on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor therapy and are accompanied by EGFR T790M mutation positive and lung adenocarcinoma.

Befortinib mesylate (BPI-D0316) is under development for the treatment of non-small cell lung cancer. The drug candidate is a third-generation EGFR inhibitor. It is administered through oral route in the form of suspension. It acts by targeting epidermal growth factor receptor (EGFR).

InventisBio overview

InventisBio is a biotechnology company focused on discovery and development of novel therapeutics in the areas of oncology and metabolic diseases. The company is headquartered in Shanghai, China.

For a complete picture of Befotertinib’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.